#Zepatier

Genotype 3 of hepatitis C virus is typically difficult to treat.

More than 125,000 veterans will have received lifesaving cures by October 2018.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.

Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.

A recent analysis of data from a roster of clinical trials yielded reassuring findings for this group of women who have hepatitis C.

A Swiss research program tested for and treated hep C in a large cohort of HIV-positive men who have sex with men over time.

In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.

This is according to a recent study of a group of European men who have sex with men who were likely infected sexually.

In a recent small study, those who received such kidneys cured the virus through standard treatment.

Fighting Hep C, using the fury to stoke the fire within.

This is according to a study including those with genotypes of hepatitis C other than genotype 1.

A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC

The ongoing cohort of men who have sex with men living with HIV had a hep C prevalence rate of about 5 percent.